Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2021 | Impact of intact P-Rmass on ICI response in mRCC

Hamid Emamekhoo, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI, discusses the results of a retrospective analysis of 209 patients with metastatic renal cell carcinoma (mRCC) previously treated with first- or second-line immune checkpoint inhibitors (ICIs). The goal of this study was to investigate the impact of having an intact primary renal mass (P-Rmass) on response to systemic treatment with ICIs. The study found that the overall radiographic response to ICIs in the first- or second-line was numerically higher in patients with an intact P-Rmass compared to patients who had had nephrectomy, however this difference was not statistically significant. This interview took place during the 2021 Genitourinary Cancers Symposium.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.